A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

METAIRIE, La. (WVUE) - A federal judge’s decision last week to restrict compounding pharmacies from producing tirzepatide, the generic version of Eli Lilly’s weight loss drug Zepbound ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Credit: Eviart via Shutterstock. A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and tirzepatide leads to significant reductions in HbA1c levels and body weight ...

View all available purchase options and get full access to this article.

Com­pound­ing phar­ma­cies faced a ma­jor set­back in their case over the FDA’s de­ci­sion to re­move the obe­si­ty drug tirzepatide from its of­fi­cial short­age list. … ...